Coumadin Use, DVT & PE : Further FAA Medical Workup
AME Assisted Special Issuance (AASI) is a
Guidance is compiled and interpreted by professional pilots and physicians at FlightPhysical.com from the 2014 AME Guide page 264, FAA and FDA web data (www.FAA.gov & www.FDA.gov), instructions specified in the Aeronautical Information Manual, Federal Air Surgeon Bulletins from 1999-2015, and 14 CFR Part 61 and Part 67 (the FARs).
AME Assisted Special Issuance (AASI) is a process that provides Examiners the ability to re-issue an airman medical certificate under the provisions of an Authorization for Special Issuance of a Medical Certificate (Authorization) to an applicant who has a medical condition that is disqualifying under Title 14 of the Code of Federal Regulations (14 CFR) part 67.
An FAA physician provides the initial certification decision and grants the Authorization in accordance with 14 CFR § 67.401. The Authorization letter is accompanied by attachments that specify the information that treating physician(s) must provide for the re-issuance determination. If this is a first-time application for an AASI for using Coumadin, and the applicant has all the required medical information necessary for a determination, the AME must defer and submit all of the documentation to the AMCD or the Regional Flight Surgeon for the initial determination.
AMEs may re-issue an airman medical certificate under the provisions of an Authorization, if the applicant provides the following:
- An Authorization granted by the FAA;
- A summary of the applicant's medical condition since the last FAA medical examination, including a statement regarding any further episodes of DVT, PE or other complication of hypercoagulopathy (see below*);
- The name and dosage of medication(s) used for treatment and/or prevention with comment regarding side effects; and
- A minimum of monthly International Normalized Ratio (INR) results for the immediate prior 6 months for those being treated with warfarin (Coumadin).
The AME must defer to the AMCD or Region if:
- More than 20 percent of INR values are < 2.0 or > 3.0 for those being treated with warfarin (Coumadin); or
- The applicant develops thrombosis (blood clot), emboli (clot that breaks off an moves in the circulatory system) or any bleeding that required medical intervention, or any other cardiac or neurologic condition previously not diagnosed or reported.
- See also the Full Protocol for Thromboembolic Disease (FAA Decision Consideration/Disease Protocol)
This page discussed Coumadin Use, DVT & PE : Further FAA Medical Workup
Reminder: use FlightPhysical.com to familiarize yourself with aviation medical regulations and guidelines, but always discuss your specific situation with one or more AMEs before dedicating resources toward expensive clinical workups. Find an AME now